Navigation Links
Honeywell and Pro-Lab Sign Distribution Agreement for Laboratory Chemicals in Turkey
Date:12/3/2009

SEELZE, Germany, Dec. 3 /PRNewswire/ -- Honeywell (NYSE: HON) announced today a multi-year distribution agreement with Pro-Lab Laboratuar Teknolojileri, which will distribute Honeywell's Burdick & Jackson® high-purity solvents in Turkey.

Burdick & Jackson solvents are used extensively by biotechnology and pharmaceutical companies in the drug discovery and evaluation process.

"The annual growth rate of the Turkish pharmaceutical market is estimated to be between 8 percent and 9 percent in the next four years. This places Turkey among the high-potential pharmaceutical markets in the region, and we are glad to be have a strong partner there," said Daniel Nott, the regional leader for Honeywell's Health Care and Packaging business in Europe, Middle East and Africa. "This agreement will further help position us as a leading company in providing a wide range of high-purity solvents for research and development in the region."

Pro-Lab, based in Istanbul, is a leading distributor of a wide range of materials and equipment for laboratories in Turkey. Gokhan Aydogan, general manager of Pro-Lab, said both companies aim to provide quality offerings and high levels of service to the high-purity solvents market in Turkey. "We believe there are a lot of untapped opportunities to be explored, especially in the booming pharmaceutical industry," Aydogan said.

Honeywell's high-purity solvents are critical to the successful research, development and approval cycle of pharmaceuticals. Major applications include analytical instrumental analysis, such as high-performance liquid chromatography (HPLC), as well as pilot and full scale production of pharmaceuticals. Honeywell also offers reagents for DNA and RNA synthesis. Honeywell manufactures its solvents for the Turkish market at its production facility in Seelze, Germany.

The agreement with Pro-Lab expands Honeywell Burdick & Jackson's distribution network in Europe, Middle East and Africa. In Germany and Austria, Honeywell's high-purity solvents are distributed by OMNI Life Science; the Irish market is supplied by Reagecon Diagnostics; the Swiss market by Thommen-Furle; the markets in Sweden, Norway and Denmark by Saveen Werner.

For more information, visit www.burdickandjackson.eu or www.pro-lab.com.tr.

Honeywell's Health Care and Packaging business is part of Honeywell Specialty Materials, a global leader in providing customers with high-performance specialty materials, including fluorine products; specialty films and additives; advanced fibers and composites; intermediates; specialty chemicals; electronic materials and chemicals; and technologies and materials for petroleum refining.

Honeywell International (www.honeywell.com) is a Fortune 100 diversified technology and manufacturing leader, serving customers worldwide with aerospace products and services; control technologies for buildings, homes and industry; automotive products; turbochargers; and specialty materials. Based in Morris Township, N.J., Honeywell's shares are traded on the New York, London, and Chicago Stock Exchanges. For more news and information on Honeywell, please visit www.honeywellnow.com.

This report contains "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934. All statements, other than statements of fact, that address activities, events or developments that we or our management intend, expect, project, believe or anticipate will or may occur in the future are forward-looking statements. Forward-looking statements are based on management's assumptions and assessments in light of past experience and trends, current conditions, expected future developments and other relevant factors. They are not guarantees of future performance, and actual results, developments and business decisions may differ from those envisaged by our forward-looking statements. Our forward-looking statements are also subject to risks and uncertainties, which can affect our performance in both the near- and long-term. We identify the principal risks and uncertainties that affect our performance in our Form 10-K and other filings with the Securities and Exchange Commission.

SOURCE Honeywell


'/>"/>
SOURCE Honeywell
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. 2009 H1N1 Flu Test From Quest Diagnostics Now CE Marked For International Distribution Under The Simplexa(TM) Brand Name
2. Mach 7 Technologies and Data Distributing Sign Agreement for U.S. Distribution of Enterprise Image Management Solutions
3. Misonix Announces New Distribution Agreement for Argentina
4. Millar Instruments and Transonic Systems, Suppliers of Gold Standard Pressure and Flow Products, Enter Into Mutual Distribution Agreement
5. Misonix Announces New Distribution Agreement For The United Arab Emirates (UAE)
6. Millar Instruments and Harvard Apparatus Improve Ability to Provide Customers With Total Physiology Solutions Through Joint Distribution Agreement
7. Misonix Announces New Distribution Agreement for Saudi Arabia and Other Middle Eastern Countries
8. Health Robotics Reaches 100% Asia-Pacific Coverage Through its New Exclusive Distribution Contract With BioRobotics in Korea
9. PLC Systems Reports Third Quarter 2009 Results; Announces Distribution Agreement for RenalGuard(R) in Brazil
10. PLC Systems Announces Distribution Agreement for RenalGuard(R) in Brazil
11. Sigma-Aldrich Enters Distribution Agreement With Stemgent, Inc. to Offer Lentivirus-Based Gene Delivery Products for Regenerative Medicine and Stem Cell Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... -- One of Australia,s successful biotechnology scientists, ... new biotechnology company, Noxopharm Limited [ABN 50 608 966 123] ("Noxopharm"). ... list on the ASX. Noxopharm is a clinic-ready company ... Phase 1 clinical study later this year. ... biggest problems facing cancer patients - the ability of cancers to ...
(Date:6/26/2016)... , June 27, 2016 Jazz Pharmaceuticals ... waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of ... acquisition of Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: ... p.m. (Eastern Daylight Time). As previously announced ... into a definitive merger agreement under which Jazz Pharmaceuticals ...
(Date:6/26/2016)... -- VMS Rehab Systems, Inc. ( www.vmsrehabsystemsinc.com ) reported today ... to build a strong and stable market for trading ... the OTC Markets-pink current trading platform. Explains ... seeing an anomaly in market trading activities that may ... Company, but shareholders and market players as well. I ...
Breaking Medicine Technology:
(Date:6/27/2016)... Dublin, CA (PRWEB) , ... June 27, 2016 ... ... Community College District , the only authorized OSHA Training Institute Education Center headquartered ... illness by protecting their workers from extreme heat at their worksites. Employers ...
(Date:6/27/2016)... ... , ... "FCPX editors can now reveal their media with growing colorful split ... Austin - CEO of Pixel Film Studios. , ProSlice Color brings the split ... now reveal the media of their split screens with growing colorful panels. , ProSlice ...
(Date:6/27/2016)... ... June 27, 2016 , ... TherapySites, ... today its affiliation with Tennessee Counseling Association. This new relationship allows ... the Tennessee Counseling Association, adding exclusive benefits and promotional offers. , "TCA is ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... industry today announced its strategic partnership with Connance, a healthcare industry leader ... two companies’ proven, proprietary technology combine to provide health systems, hospitals and ...
(Date:6/27/2016)... ... 2016 , ... A revolution is underway. Brooklyn-based company, ... for the millions of people who require these medical transport services annually. ... the use of technology. Now, SmartEMS has put forth an industry-changing app that ...
Breaking Medicine News(10 mins):